Clinical impacts of mesothelin expression in gastrointestinal carcinomas

Takahiro Einama, Futoshi Kawamata, Hirofumi Kamachi, Hiroshi Nishihara, Shigenori Homma, Fumihiko Matsuzawa, Tatsuzo Mizukami, Yuji Konishi, Munenori Tahara, Toshiya Kamiyama, Okio Hino, Akinobu Taketomi, Satoru Todo

Takahiro Einama, Futoshi Kawamata, Hirofumi Kamachi, Shigenori Homma, Fumihiko Matsuzawa, Tatsuzo Mizukami, Yuji Konishi, Munenori Tahara, Toshiya Kamiyama, Akinobu Taketomi, Department of General Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan

Hiroshi Nishihara, Department of Translational Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan

Okio Hino, Department of Pathology and Oncology, Juntendo University School of Medicine, Tokyo 113-8421, Japan

Satoru Todo, Research institute of St. Mary’s Hospital, Kurume 830-8558, Japan

Author contributions: All authors equally contributed to this paper regarding its conception, literature review, editing and approval of the final version.

Conflict-of-interest statement: No potential conflicts of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Takahiro Einama, MD, PhD, Department of General Surgery, Hokkaido University Graduate School of Medicine, Kita-Ku, Kita 14, Nishi 7, Sapporo, Hokkaido 060-8638, Japan. tituehahaue@hotmail.com

Telephone: +81-11-7065927
Fax: +81-11-7177515

Received: September 29, 2015

Peers-review started: October 2, 2015
First decision: November 4, 2015
Revised: December 8, 2015
Accepted: January 27, 2016
Article in press: January 29, 2016
Published online: May 15, 2016

Abstract

Mesothelin, C-ERC/mesothelin is a 40-kDa cell surface glycoprotein that is normally present on normal mesothelial cells lining the pleura, peritoneum, and pericardium. Moreover, mesothelin has been shown to be overexpressed in several human cancers, including virtually all mesothelioma and pancreatic cancer, approximately 70% of ovarian cancer and extra bile duct cancer, and 50% of lung adenocarcinomas and gastric cancer. The full-length human mesothelin gene encodes the primary product, a 71-kDa precursor protein. The 71-kDa mesothelin precursor is cleaved into two products, 40-kDa C-terminal fragment that remains membrane-bound via glycosylphosphatidylinositol anchor, and a 31-kDa N-terminal fragment, megakaryocyte potentiating factor, which is secreted into the blood. The biological functions of mesothelin remain largely unknown. However, results of recent studies have suggested that the mesothelin may play a role of cell proliferation and migration. In pancreatic cancer, mesothelin expression was immunohistochemically observed in all cases, but absent in normal pancreas and in chronic pancreatitis. Furthermore, the expression of mesothelin was correlated with an poorer patient outcome in several human cancers. The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy. The present review discusses the expression and function of mesothelin in cancer cells and the utility of mesothelin as...
Mesothelin could play a role of the binding to CA125 adenocarcinoma with unfavorable patient outcome in pancreatic ductal adenocarcinoma. The co-expression of mesothelin and CA125 correlates with an unfavorable patient outcome in several human cancers. The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy.

**Key words:** Mesothelin; Luminal membrane expression; Cytoplasmic expression; Tumor marker; Cancer therapy

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Mesothelin is a 40-kDa cell surface glycoprotein expressed on normal mesothelial cells lining the pleura, pericardium, and peritoneum. Moreover, mesothelin has been shown to be overexpressed in several cancer types. Recent studies have suggested that the overexpression of mesothelin increases cell proliferation and migration. Furthermore, the expression of mesothelin was related to an unfavourable patient outcome in several human cancers. The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy.

**INTRODUCTION**

Mesothelin is a 40-kDa cell surface glycoprotein that is normally present on normal mesothelial cells lining the pleura, pericardium, and peritoneum.[1,2] Moreover, mesothelin has been shown to be overexpressed in several human cancers, including virtually all mesothelioma and pancreatic cancer, approximately 70% of ovarian cancer and extra bile duct cancer, and 50% of lung adenocarcinomas and gastric cancer.[3-6] (Table 1). The full-length human mesothelin gene (Full-ERC/mesothelin) encodes a 71-kDa precursor protein. The 71-kDa mesothelin precursor is cleaved into two products, 40-kDa C-terminal fragment (C-ERC/mesothelin) that remains membrane-bound via glycosylphosphatidylinositol anchor[7], and a 31-kDa N-terminal fragment (N-ERC/mesothelin, megakaryocyte potentiating factor), which is secreted into the blood (Figure 1)[10]. The function of mesothelin in cancer is still unclear. However, results of recent studies have suggested that the mesothelin may play a role of tumor progression in vitro[8-11] and in vivo.[11,12]

**MESOTHELIN EXPRESSION IN GASTROINTESTINAL CANCERS**

**Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma**

Mesothelin could play a role of the binding to CA125[13-15]. Mesothelin and CA125 binding may be important in the peritoneal spread.[13,15] In ovarian cancer, advanced clinical stage and/or high histological grade patients showed mesothelin expression and CA125 expressions.[15] Our group showed that the co-expression of mesothelin and CA125 group was a higher histological grade and a higher level of blood vessel permeation and correlated with recurrence rate and poor patient outcome in pancreatic ductal adenocarcinoma[16]. These findings suggest that the co-expression of mesothelin and CA125 may lead to tumor development, metastasis, and a poorer patient prognosis.

**Luminal membrane expression of mesothelin is a prominent poor prognostic factor**

The expression of mesothelin was related to an unfavorable patient outcome in pancreatic ductal adenocarcinoma[16,17]. Our group investigated mesothelin expression in gastric cancers by using immunohistochemistry, especially focusing on the localization of mesothelin, i.e., “luminal membrane-positive” and/or “cytoplasm-positive” (Figure 2)[18].

The overall survival revealed that the “luminal membrane-positive” group showed a significantly poorer outcome compared to the “luminal membrane-negative” group. On the other hand, the “mesothelin-positive” group and the “cytoplasmic-positive” group were not correlated with overall survival in the gastric cancer patients.

Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has a histological spectrum ranging from benign adenoma to invasive cancer. We performed an immunohistochemical analysis of mesothelin expression in IPMN. Mesothelin was absent in all of the normal pancreatic tissues. But, mesothelin was expressed in both adenoma and carcinoma cells. Most of mesothelin expressed adenoma cells exhibited slight “cytoplasmic-positive”, and the “luminal membrane-positive” group has a tendency of poor prognosis and high recurrence rate[19].

Based on these results, the “luminal membrane-positive” of mesothelin is a useful prognostic factor, implying that membrane-localized mesothelin might have the significant function of the aggressive behavior in the cancer cells.

**THE ROLE OF MESOTHELIN EXPRESSION IN TUMOR BIOLOGY**

Our study generated the novel finding, the potential role of the “luminal membrane-positive” mesothelin in the malignant behavior of tumor cells.[18,21] The human mesothelin gene encodes a 71-kDa precursor protein (Full-ERC/mesothelin). This precursor protein is cleaved by furin-like proteases into a 31-kDa N-terminal secreted form (N-ERC/mesothelin) and a C-terminal fragment, 40-kDa mesothelin (C-ERC/mesothelin).[17,22]. The 5B2 anti-mesothelin antibody, which we used in our studies,
can detect the 71-kDa precursor protein (Full-ERC/mesothelin) and the 40-kDa C-terminal fragment (C-ERC/mesothelin), but not the 30-kDa N-terminal fragment (N-ERC/mesothelin). Based on the specificity of this antibody, the “luminal membrane-positive” mesothelin observed in our study might have indicated the existence of 40-kDa mesothelin (C-ERC/mesothelin) membrane-bound form, while the “cytoplasmic-positive” mesothelin might have indicated the presence of the 71-kDa precursor protein (Full-ERC/mesothelin). To demonstrate the mechanism of the membranous localization of mesothelin, we enforced the expression of Full-, C-, and N-ERC/mesothelin in human colorectal cancer (CRC) cell lines. The 7E7 antibody, which recognizes the 30-kDa N-terminal fragment (N-ERC/mesothelin), revealed the diffuse cytoplasmic expression of Full- and N-ERC/mesothelin in Full-WiDr and N-WiDr. In contrast, the 22A31 antibody, which recognizes 40-kDa mesothelin (C-ERC/mesothelin), demonstrated a dot-like expression of Full- and C-ERC/mesothelin in Full-WiDr and C-WiDr. Moreover, some of the dot-like spots along with the cellular membrane were merged with actin, showing yellow signals. According to these results, we confirmed the membranous expressions of C-ERC/mesothelin in CRC cell lines.

To demonstrate the biological role of Full-, C-, and N-ERC/mesothelin in the lymphatic invasion of CRC, we performed an in vitro lymphatic invasion assay. C-ERC/mesothelin, the 40-kDa membrane-localized fragment, promoted the lymphatic invasion by increasing cell adhesion to lymphatic endothelial cells.

**THE PATHWAYS OF MESOTHELIN INVOLVED IN CANCER**

Recent studies reported that mesothelin is not only associated with increased cell proliferation and the migration of pancreatic cancer cells in vitro, but also contributes to tumor progression in vivo. Mesothelin protects cancer cells from paclitaxel-induced apoptosis through both the concomitant activation of PI3K/Akt and MAPK/ERK pathways. Overexpression of mesothelin in pancreatic cancer cells leads to constitutive activation of signal transducer and activator of transcription 3, which results in enhanced expression of cyclin E and cyclin...
E/cyclin-dependent kinase 2 complex formation as well as increased G1-S transition[21]. Mesothelin expression correlated closely with interleukin (IL)-6 in human pancreatic cancer specimens and cell lines. Cancer cell with forced mesothelin expression grow faster than control cells by producing higher quantities of IL-6[20,21].

**BLOOD TEST FOR MESOTHELIN**

Several ELISAs have been developed to measure the levels of soluble mesothelin-related peptide (SMRP) and megakaryocyte potentiating factor (MPF, N-ERC/mesothelin). The soluble form of mesothelin is likely due to an abnormal splicing event resulting in a frameshift mutation and premature termination at amino acid 600 deleting the amino acids at the COOH terminus that are responsible for its association with the cell membrane. The full-length human mesothelin gene encodes the primary product, a 71-kDa precursor protein. It can be physiologically cleaved by some furin-like proteases into a 40-kDa C-terminal fragment that remains membrane-bound, and a 31-kDa N-terminal fragment, which is secreted into the blood. The C-terminal 40-kDa fragment is referred to as mesothelin. In contrast, the N-terminal 31-kDa fragment is a secreted protein identified as MPF. SMRP has proven to be a promising cancer biomarker in the sera of patients with tumors of mesothelial origin[25,26]. MPF has been reported to be expressed in gastrointestinal cancer[27,28]. Wu et al[29] revealed that SMRP performs better than CA125 as a tumor marker for epithelial ovarian cancer, it increases only in malignant patients and not in benign patients or healthy volunteers. Furthermore, the sensitivity is enhanced when combined with CA125. Hassan et al[30] identified a positive correlation with the tumor burden and SMRP levels, as a marker for monitoring the response to treatment of malignant mesothelioma.

**MESOTHELIN TARGET IMMUNOTHERAPY**

Because of the high expression of mesothelin in many malignancies and its limited expression in normal tissues, mesothelin has been suggested as an attractive target for immunotherapy. Several therapeutic agents that target mesothelin have been developed and some are being evaluated in preclinical and clinical studies. SS1P is an immunotoxin being clinically tested as a systemic agent in solid tumor patients. Two phase I trials of single-agent SS1P have been performed[31,32]. The majority of patients developed antidrug antibodies by the end of their first cycle, resulting in non-therapeutic drug levels if any additional cycles were given. MORAB-009 (amatumiximab) is a chimeric antibody. A phase I clinical trial of MORAB-009 for mesothelioma, pancreatic cancer, and ovarian cancer patients has been completed[33]. Eleven of 24 subjects had stable disease. Phase I/II studies of MORAB-009 in different mesothelin-expressing cancers are ongoing. The mesothelin tumor vaccine in clinical development is CRS-207. The safety of this vaccine was established in a phase I clinical trial of patients with mesothelin-expressing refractory cancers[34].

**CONCLUSION**

Mesothelin is an attractive antigen that is expressed in several gastrointestinal cancers. Recent studies have revealed oncogenic functions of mesothelin in cancer proliferation and invasion and drug resistance. Also, soluble mesothelin could be useful as a tumor marker. The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy.

**REFERENCES**

1. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesotheliunum, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996; 93: 136-140 [PMID: 8552591 DOI: 10.1073/pnas.93.1.136]

2. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesotheliunum. Int J Cancer 1992; 50: 373-381 [PMID: 1735605 DOI: 10.1002/ijc.2910500308]

3. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffe E, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001; 7: 3862-3868 [PMID: 11751476]

4. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005; 13: 243-247 [PMID: 16082249 DOI: 10.1097/01.pai.0000141545.36485.d6]

5. Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003; 16: 192-197 [PMID: 12640077 DOI: 10.1097/01.mp.0000056981.16578.c3]

6. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003; 27: 1418-1428 [PMID: 14576474 DOI: 10.1097/00000478-200311000-00003]

7. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immuno-therapy. Clin Cancer Res 2004; 10: 3937-3942 [PMID: 15217923 DOI: 10.1118/1078-0432.CCR-03-0801]

8. Wang K, Bodempudi V, Liu Z, Borrego-Díaz E, Yamoutpoor F, Meyer A, Woo RA, Pan W, Dudek AZ, Olayee MS, Esfandyari T, Farassati F. Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS One 2012; 7: e33214 [PMID: 22485139 DOI: 10.1371/journal.pone.0033214]

9. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 2011; 32: 1013-1024 [PMID: 21515913 DOI: 10.1093/carcin/bgr075]

10. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNF-a-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Mol Cancer 2011; 10: 106 [PMID: 21880146 DOI: 10.1186/1476-4598-10-106]

11. Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, Brunicardi FC, Chen C, Yao Q. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008; 7: 286-296 [PMID: 18281514 DOI: 10.1158/1535-7163.MCT-07-0483]

12. Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, Rusch VW, Sadanlin M, A’dasumilli PS. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma
Einama T et al. Mesothelin expression in gastrointestinal carcinomas

patients. Clin Cancer Res 2012; 18: 2478-2489 [PMID: 23274155 DOI: 10.1186/1541-7786-34-11-S1-61]

13 Gubbels JA, Belisle J, Onda M, Rancourt C, Mignault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patanak MS. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006; 5: 50 [PMID: 17067392 DOI: 10.1186/1476-4598-5-50]

14 Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, Ho M. A binding domain on mesothelin for CA125/MUC16. J Biol Chem 2009; 284: 3739-3749 [PMID: 19075018 DOI: 10.1074/jbc.M806776200]

15 Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004; 279: 9190-9196 [PMID: 14676194 DOI: 10.1074/jbc.M312372200]

16 Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K, Sasaki A, Tahara M, Okada K, Muroaka S, Kamiyama T, Matsumo Y, Ozaki M, Todo S. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas 2011; 40: 1276-1282 [PMID: 21775916 DOI: 10.1097/MPA.0b013e318221bed8]

17 Shimizu A, Hirose T, Tani M, Kawai M, Okada K, Miyazawa M, Kitahata Y, Nakamura Y, Noda T, Yokoyama S, Yamae H. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci 2012; 103: 739-746 [PMID: 22320398 DOI: 10.1111/j.1349-7006.2012.02214.x]

18 Einama T, Homma S, Kamachi H, Kawamata F, Todo S. Importance of luminal membrane mesothelin expression in human gastric cancer. Int J Oncol 2006; 28: 447-453 [PMID: 16298485 DOI: 10.1186/1078-0432-CCR-05-1477]

19 Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K, Sasaki A, Tahara M, Okada K, Muroaka S, Kamiyama T, Taketomi A, Matsumo Y, Furukawa H, Todo S. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelin-expressing cancers. Int J Oncol 2009; 35: 5274-5279 [PMID: 19671873 DOI: 10.1186/1078-0432-35-5006]

20 Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelin-expressing carcinomas. Clin Cancer Res 2006; 12: 447-453 [PMID: 16298485 DOI: 10.1186/1078-0432-35-5006]

21 Hassan R, Broadus VC, Wilson S, Liewehr DJ, Zhang J. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 2007; 13: 7166-7171 [PMID: 18056197 DOI: 10.1186/1078-0432-CC-07-1592]

22 Creelman TH, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009; 15: 5274-5279 [PMID: 19671873 DOI: 10.1186/1078-0432-CC-09-0062]

23 Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 2010; 16: 6132-6138 [PMID: 21037025 DOI: 10.1186/1078-0432-CC-10-2275]

24 Le DT, Brockstedt DG, Nir-Paz R, Hampel J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illies P, Dubensky TW, Eiden JE, Jaffee EM, Laheru DA. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction. Clin Cancer Res 2010; 16: 858-868 [PMID: 22147941 DOI: 10.1186/1078-0432-CC-11-2121]

25 Baba K, Ishigami S, Ariigami T, Uenosono Y, Okumura H, Matsumoto M, Kurasu H, Uchikado Y, Kita Y, Kijima Y, Kitazono M, Shinchi H, Ueno S, Natsugoe S. Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 2012; 105: 195-199 [PMID: 21780126 DOI: 10.1002/jso.22024]

P-Reviewer: Munoz M, Zhu YL
S-Editor: Qin S L-Editor: A E-Editor: Li D
